Meetings: Advisory Committee Information Hotline,

[Federal Register: December 18, 2003 (Volume 68, Number 243)]

[Notices]

[Page 70512-70513]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr18de03-53]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee Information Hotline

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that we have revised the Advisory Committee Information Hotline (the hotline). The hotline provides the public with access to the most current information available on FDA advisory committee meetings. This notice supersedes all previously published announcements of FDA's Advisory Committee Information Hotline.

FOR FURTHER INFORMATION CONTACT: Theresa L. Green, Committee Management Officer (HF-4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1220.

SUPPLEMENTARY INFORMATION: The Advisory Committee Information Hotline can be accessed by dialing 1-800-741-8138 or 301-443-0572. The advisory committee meeting information and information updates can also be accessed via FDA's Advisory Committee calendar at http://www.fda.gov/oc/advisory/accalendar/accalendar.html .

Each advisory committee is assigned a 10-digit number. This 10- digit number will appear in each individual notice of meeting. The public can obtain information about a particular advisory committee meeting by using the committee's 10-digit number. Information on the hotline is preliminary and may change before a meeting is actually held. The hotline will be updated when such changes are made. The following is a list of each advisory committee's 10-digit number to be used when accessing the hotline.

ADVISORY COMMITTEE

NUMBER

OFFICE OF THE COMMISSIONER.............................................. Science Board to the FDA................... 3014512603 CENTER FOR BIOLOGICS EVALUATION AND RESEARCH............................ Allergenic Products Advisory Committee..... 3014512388 Biological Response Modifiers Advisory 3014512389 Committee. Blood Products Advisory Committee.......... 3014519516 Transmissible Spongiform Encephalopathies 3014512392 Advisory Committee. Vaccines and Related Biological Products 3014512391 Advisory Committee. CENTER FOR DRUG EVALUATION AND RESEARCH................................. Anesthetic and Life Support Drugs Advisory 3014512529 Committee. Anti-Infective Drugs Advisory Committee 3014512530 (Peds SubC). Antiviral Drugs Advisory Committee......... 3014512531 Arthritis Advisory Committee............... 3014512532 Cardiovascular and Renal Drugs Advisory 3014512533 Committee.

[[Page 70513]]

Dermatologic and Ophthalmic Drugs Advisory 3014512534 Committee. Drug Safety and Risk Management Advisory 3014512535 Committee (Drug Abuse Subcommittee). Endocrinologic and Metabolic Drugs Advisory 3014512536 Committee. Gastrointestinal Drugs Advisory Committee.. 3014512538 Nonprescription Drugs Advisory Committee... 3014512541 Oncologic Drugs Advisory Committee......... 3014512542 Peripheral and Central Nervous System Drugs 3014512543 Advisory Committee. Pharmaceutical Science, Advisory Committee 3014512539 for. Psychopharmacologic Drugs Advisory

3014512544 Committee. Pulmonary-Allergy Drugs Advisory Committee. 3014512545 Reproductive Health Drugs, Advisory

3014512537 Committee for. CENTER FOR FOOD SAFETY AND APPLIED NUTRITION............................ Food Advisory Committee (full committee and 3014510564 subcommittees).

Additives and Ingredients Subcommittee .........................

Biotechnology Subcommittee...............

Contaminants and Natural Toxicants Subcommittee.

Dietary Supplements Subcommittee.........

Infant Formula Subcommittee..............

Nutrition Subcommittee................... CENTER FOR DEVICES AND RADIOLOGICAL HEALTH.............................. Device Good Manufacturing Practice Advisory 3014512398 Committee. Medical Devices Advisory Committee

N/A (comprised of 18 panels).

Anesthesiology and Respiratory Therapy 3014512624 Devices Panel.

Circulatory System Devices Panel......... 3014512625

Clinical Chemistry and Clinical

3014512514 Toxicology Devices Panel.

Dental Products Panel.................... 3014512518

Ear, Nose, and Throat Devices Panel...... 3014512522

Gastroenterology-Urology Devices Panel... 3014512523

General and Plastic Surgery Devices Panel 3014512519

General Hospital and Personal Use Devices 3014512520 Panel.

Hematology and Pathology Devices Panel... 3014512515

Immunology Devices Panel................. 3014512516

Medical Devices Dispute Resolution Panel. 3014510232

Microbiology Devices Panel............... 3014512517

Molecular and Clinical Genetics Panel.... 3014510231

Neurological Devices Panel............... 3014512513

Obstetrics-Gynecology Devices............ 3014512524

Ophthalmic Devices Panel................. 3014512396

Orthopaedic and Rehabilitation Devices 3014512521 Panel.

Radiological Devices Panel............... 3014512526 National Mammography Quality Assurance 3014512397 Advisory Committee. Technical Electronic Product Radiation 3014512399 Safety Standards Committee. CENTER FOR VETERINARY MEDICINE.......................................... Veterinary Medicine Advisory Committee..... 3014512548 NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH.............................. Science Advisory Board to NCTR............. 3014512559 Advisory Committee on Special Studies

3014512560 Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants.

The hotline will provide the most recent information available on upcoming advisory committee meetings, guidance for making an oral presentation during the open public hearing portion of a meeting, and procedures on obtaining copies of transcripts of advisory committee meetings. Because the hotline will communicate the most current information available about any particular advisory committee meeting, this system will provide interested parties with timely and equal access to such information. The hotline should also conserve agency resources by reducing the current volume of inquiries individual FDA offices and employees must handle concerning advisory committee schedules and procedures.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

Dated: December 10, 2003. Peter J. Pitts, Associate Commissioner for External Relations.

[FR Doc. 03-31157 Filed 12-17-03; 8:45 am]

BILLING CODE 4160-01-S